A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2018
At a glance
- Drugs U3 1402 (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 26 Sep 2018 Enrollment to Dose Escalation cohort 1 was completed in April 2018, as per trial design presented at the 19th World Conference on Lung Cancer.
- 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
- 05 Jun 2018 Enrollment to cohort 1 began in January 2018 as per trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology